Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-
BA3526 TNF-α-IN-2Summary: TNF-α-IN-2 is a potent and orally active tumor necrosis factor alpha inhibitor. - BA3527 DRI-C21045Summary: DRI-C21045 is a potent and selective inhibitor of co-stimulatory protein-protein interactions (PPIs).
- BA3528 UCB-5307Summary: UCB-5307 is an inhibitor.
- BA3530 BenpyrineSummary: Benpyrine is a highly specific inhibitor with oral activity.
- BA3531 TNF-α-IN-6Summary: TNF-alpha-IN-6 is an orally potent variant inhibitor.
- BA3532 TebentafuspSummary: Tebentafusp (IMCgp100) is a bispecific fusion protein targeting (a melanoma-associated antigen).
- BA3533 HomoplantagininSummary: Flavonoids with anti-inflammatory and antioxidant activity from Chinese herbs.
- BA3534 AX-024Summary: AX-024 is an orally available, first-in-class interaction inhibitor that selectively inhibits TCR-triggered T cell activation.
- BA3535 FrexalimabSummary: Frexalimab (SAR441344; INX-021) is a monoclonal antibody that targets the ligand.
- BA3537 SciadopitysinSummary: Sciadopitysin is a biflavonoid from Ginkgo biloba.